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The explosion of genome sequencing data along with genotype to phenotype correlation studies has created data
deluge in the area of biomedical sciences. The aim of the Medical bioinformatics section is to aid the development
and maturation of the field by providing a platform for the translation of these datasets into useful clinical
applications. The increase in computing capabilities and availability of different data from advanced technologies
will allow researchers to build System Biology models of various diseases in order to efficiently develop new
therapeutic interventions and reduce the current prohibitively large costs of drug discovery.
The section welcomes studies on the development of Biomedical Informatics for translational medicine and clinical
applications, including tools, methodologies and data integration.Launched with the promise of improving insights into
human health and disease, the Human Genome Project
a decade after its completion has revealed a wealth of in-
formation. The advent of next generation sequencing
technologies and other high throughput measurements
of ‘omics’ data, along with clinical phenotype association
studies, have created a data deluge. However, explosive
growth in biomedical data generation has not yet trans-
lated to proportionate increases in clinical returns. The
announcement of the X-prize in genomics for sequen-
cing 100 centenarians within 30 days at less than $1,000
per genome, and with an error rate less than one in a
million base pairs, is expected to herald a new era,
where whole genome sequencing will become routine
clinical practice for diagnosis and prognosis for persona-
lized healthcare [1]. However, this would only be pos-
sible if we are able to capture, curate and analyze clinical
data with ‘omics’ datasets using novel informatics tools
to establish correlations with high level of confidence.
This major transformation that hoped to bridge the gap
between researchers and clinicians will primarily be
driven by transformation of silos of biomedical research
to an integrative field of intensive data driven discovery.* Correspondence: skb@igib.res.in
1CSIR-Institute of Genomics and Integrative Biology, Mall Road, New Delhi
110007, India
2CSIR- Open Source Drug Discovery (OSDD) unit, Anusandhan Bhavan, 2 Rafi
Marg, New Delhi 110001, India
Full list of author information is available at the end of the article
© 2012 Brahmachari; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe new paradigm of scientific discovery arising out of
this data exploration is referred to as the “Fourth Para-
digm” [2] and combines data capture, theory and compu-
tation. This paradigm rests on the power of information
technology and advance computing facility to effectively
mine semantically linked datasets to derive patterns and
predictive models.
‘Medical Bioinformatics’ holds immense promise in this
area by equipping researchers with tools and resources
to efficiently capture, curate and analyze the ‘big data’,
while allowing clinicians and care-givers access to evi-
dence based insights which could be effectively used for
patient-care.
The initial efforts on data collection of genotype-to-
phenotype correlation studies have largely been carried
under the Genome Wide Association studies (GWAS). Al-
though the studies have contributed immensely towards
exploring the genetic basis of complex diseases, many of
the insights obtained by these studies could not be opti-
mally extrapolated to clinical settings due to poor predict-
ability of traits exclusively based on genetic markers,
baring a few exceptions. Large-scale integrative analyses of
these datasets are primarily limited by non-standard
phenotype descriptions and limitations with data sharing
due to ethical constrains. The field of genotype-to-
phenotype association study requires new and effective
measures to integrate standardized genotype and pheno-
type information, so as to enable their easy access and
robust analyses by the researchers. The GEN2PHEN, isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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organize the web-based genetic information that funda-
mentally impacts human health and disease prognosis [3].
The project has achieved significant success in facilitating
holistic viewing of genotype-to-phenotype (G2P) correla-
tions by systematically integrating genetic variation data-
bases of the human and model organisms, and further
linking it to other biomedical knowledge sources through
genome browser functionality.
While organizing existing datasets still remains a chal-
lenge, it is evident that the next generation of biosensors
and electronic gadgets which can collect and transmit
information on vital signs and clinical parameters
coupled with ubiquitous connectivity are poised to be
the next big revolution in personalized healthcare, ge-
nerating voluminous data on individuals. Systematic
organization, and mining of this large repository of cli-
nical information, derived from sensors, diagnostic labs
and harnessing it for cost-effective and personalized
healthcare would be a major challenge in the immediate
future and has raised the need for new data handling, in-
tegration and web-based community workspace tools.
The emerging concept of ‘cloud computing’ has the po-
tential to address these concerns. Cloud computing allows
for collection and storage of clinical data in an advanced
information technology enabled fashion. Information
transmitted through biosensors could be received and
stored in a transparent manner and in a standardized elec-
tronic format. The information could be archived with
additional non-clinical parameters, thus forming the basis
of a biomedical database. Such cloud computing will in-
crease the access and the workflow of electronic data to
enable accurate analysis towards the discovery of new pre-
dictive biomarkers for disease predisposition.
The advancement in techniques for data capture and
curation of different types of data will further encourage
adoption of an integrated, ‘System Biology’ platform for
studying and analyzing these datasets. This approach will
enable designing of accurate predictive mathematical
models to study biological systems- intracellular net-
works, cells, organs, and any biological entity—by mea-
suring and integrating genetic, proteomic and metabolic
data. With respect to drug discovery, application of this
approach will involve utilizing clinical samples from dis-
eased and healthy (normal) individuals to uncover sys-
tem biology markers and pathways targets, which are
indicators of disease and potential targets for therapeutic
interventions. Such efficient identification of novel drug
target leads thus, has the potential to reduce the current
prohibitively large costs of drug discovery by eliminating
trial and error methods.
It is also worth mentioning that the big data science of
medical bionformatics, which has attracted big attention
of funding agencies [4] will engage the expertise ofmedical scientists, bioinformaticians, computer scien-
tists, and database experts, along with mathematicians
and engineering experts in modelling and simulation of
biosystems, with an objective of developing novel low-
cost therapeutic applications. The Open Source Drug
Discovery (OSDD) initiative [5,6] for system level under-
standing of Mycobacterium tuberculosis has created a
new paradigm for distributed co-creation through crowd
sourcing [7] and the application of social media for data
gathering. This is going to be the new frontier of appli-
cation of bioinformatics in medical research.
The Medical bioinfromatics section in Journal of
Translational Medicine would aim to promote research
in this area by providing a high-quality publishing media
for path-breaking and innovative research in the area.
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